Company Biography
Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC) with Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EMPOWER-Lung 1 Brain Metastases Subpopulation
Link to Abstract. A PDF of the poster is available to download under the Resources tab
Contact Information
Name
Mustafa Özgüroğlu
Email
ozguroglu@gmail.com
You have chosen to your
information with
Patient-Reported Outcomes (PROs) in Patients (pts) with Advanced Non-Small Cell Lung Cancer (aNSCLC) with Programmed Cell Death-Ligand 1 (PD-L1) ≥50% Receiving Cemiplimab (CEMI) Monotherapy Versus Platinum-Doublet Chemotherapy (CHEMO): A Focus on the EM-
Team Members
Mustafa Özgüroğlu
Istanbul university Cerrahpasa
Giuseppe Gullo